Search jobs
22-Sep-2022
Anesthesia, Respiratory and Sleep Management Device Market to record a CAGR of 7.4%, Majority of Growth to Originate from North America
According to a new report by Market.us, the market is expected to reach $15.31 billion by 2022 from $10.21 billion in 2017, at a CAGR of 7.4%. The growth of this market is driven by the increasing prevalence of sleep disorders and respiratory diseases, the growing number of surgical procedures, and the availability of advanced anesthesia devices. However, the high cost of these devices and the lack of skilled personnel are restraining the growth of this market. Anesthesia, respiratory and sleep management devices are integral to the delivery of modern healthcare. They allow clinicians to provide life-saving care to patients with a wide range of medical conditions. These devices enable clinicians to monitor and support a patient’s vital functions, including their breathing and heart rate. This report provides valuable information to shareholders, new entrants, frontrunners, and shareholders. It helps them formulate strategies for the future, as well as take the necessary steps to strengthen their market position. The report includes graphical representations and tabular representations to provide an in-depth analysis of every segment as well as their sub-segments. This report is intended to aid market players, investors, new entrants, and others in formulating strategies based on the fastest-growing segments and highest revenue generation. Market.us data from the latest shows that North America in 2021 will be the largest Anesthesia, Respiratory and Sleep Management Device market. Mexico, Canada and the US are experiencing nominal CAGRs of [2022-2031] above the global average. Identify the key factors that will drive your company’s growth. Request a brochure of this report here:  https://market.us/report/anesthesia,-respiratory-and-sleep-management-device-market/request-sample/
 [Sample reports can be used to check out our detailed reports and study material before purchasing] 
1. The updated 150+ page reports give an in-depth analysis and commentary on the COVID-19 virus pandemic. 2. You can find out about industry data and interviews with experts to learn more about topics like regional impact analysis, global outlook, competitive landscape analysis, market size, share, and the size of regional markets. 3. These reports are available in PDF format. You can view them on your computer or print them. 4. PDF sample report provides additional information on Major Market Players including their Sales Volume, Business Strategy, Revenue Analysis and Revenue Analysis. This gives readers an advantage over other people. 5. The Market.us Research report includes a detailed analysis of key factors that influence the market’s growth. 6. Sample report also provides insight on major market players, their business strategies, and revenue analysis to give readers an edge over others. Anesthesia, Respiratory and Sleep Management Device Market – Competitive Landscape 
Philips
Key Questions Answered in This Report: 
Q1. What is the market size of Anesthesia, Respiratory and Sleep Management Device? Q2. What are the elements of retail Anesthesia, Respiratory and Sleep Management Device? Q3. What are the key decision drivers for service buyers? Q4. How can we accelerate our bidding process? Q5. What is the potential of the Anesthesia, Respiratory and Sleep Management Device Market? Q6. Who are the prominent players in Anesthesia, Respiratory and Sleep Management Device Market? Q7. What are the different types of Anesthesia, Respiratory and Sleep Management Device market? Q8. What are the top strategies that companies adopt in Anesthesia, Respiratory and Sleep Management Device Market? Q9. What is the future of Anesthesia, Respiratory and Sleep Management Device? Trending Reports (Book Now with Save 25% [Single User], 38% [Multi-User], 45% [Corporate Users] + Covid-19 scenario+ Impact of Russia-Ukraine war):

Anesthesia, Respiratory and Sleep Management Device Market to record a CAGR of 7.4%, Majority of Growth to Originate from North America

IndianWeb2 Desk
The company offers vernacular language bedtime stories and guided meditation to make sleep more effective
Neend, India’s leading mobile-based application for sleep management has announced that it has raised $700k in its latest pre-seed round. The funding round was led by Better Capital, and saw participation from Rohit Bansal and Kunal Bahl (Founder of Snapdeal), Kunal Shah (Cred), and Nandan (Swiggy), Niraj Singh (Spinny)    Sandeep Singhal (Nexus), Lalit Keshre and Harsh Jain(Groww) among others. The funds will be utlized for linguistic expansion and create more depth in categories like Yog Nidra, guided meditation session, and music, amongst others. In addition to this, Neend will also collaborate with the professional sleep experts to help users to measure, understand, and fix their sleep. Founded in 2021 by Surbhi Jain, an IIT Bombay alumnus and serial entrepreneur, Neend aims to help individuals cope up with all sleep related problems, and provides an immersive experience with its relaxing bedtime stories, soothing sleep sounds, and ambiences. Owing to the current fast paced life, a majority of Indians are dealing with stress and anxiety which often lead to sleep deprivation, which the brand is aiming to address. Commenting on the investment, Surbhi Jain, Founder of Neend, said, “In the last 5 years due to change in our lifestyles - lack of physical exercise, increased screen time consumption, and stress, sleeplessness or  insomnia has become a very common problem. One in every 3 people has sleep troubles in the world. This has poised a huge challenge for individuals, impacting productivity levels. We wanted to build a platform that helps people address this. Through our relaxing content based approach, we are helping individuals cure insomnia and provide better quality sleep.”
In the past few months, Neend has seen tremendous growth across platforms. Their YouTube channel has more than 6.5 million views, with a subscriber base of 75000 in just a couple of months. The Neend app currently has over 50K downloads (most of these coming organically), with individuals suffering with severe insomnia issues recovering significantly and getting rid of their medication. "Insomnia is fast becoming a major problem in India and is likely to get worse. Neend is an outcome of a founder’s personal journey with sleep deprivation. Neend combines immersive content and sleep expertise in a simple single app that is designed for millions of Indian users who are suffering with little help. I am excited to partner with Surbhi & team as they build the Sleep App for India”, said Vaibhav Domkundwar of Better Capital, an early backer of innovative health tech companies like Cradlewise, Fittr, Mojocare & others. Neend is on a mission to help people have a better lifestyle by putting the right amount of focus on things which matter. The company is also working with experts to build  sleep therapy content that helps cure stress, and chronic insomnia. Advertisements

IIT Bombay Alumnus Founded Free Sleep Management App 'Neend' Raises $700K in Seed Round Led by Better Capital

You are alone on a small sailing boat, more than four thousand miles of ocean ahead and you are up against approximately 80 sailors. It will take you three or four weeks to get to the finishing line. But how will you manage to sleep and which sleeping strategy will pay off during the race? Researchers of the University of Bologna identified and analyzed the different sleeping strategies employed by solo skippers. “Especially during singlehanded transatlantic races, sailing needs a skipper that is ready to intervene rapidly and with soundness of mind in full control of his body and brain. This is the only way to be able to quickly modify the yacht route and attitude,” says Giuseppe Plazzi, MD, study coordinator and Unibo professor, in a releaes. “Moreover, sailors are forced to be vigil for long periods of time as they need to face unstable and adverse weather conditions. Appropriate sleep management even before the race can be a decisive factor in their sailing performance and safety.”
A number of sleep management strategies emerge from this study published in Nature and Science of Sleep . Some sailors stock up on sleep before the race, some others prefer short and frequent naps, while some other skippers get used to increasingly shorter sleeping periods. The study also brings to the fore a “natural selection” among sailors, one that favors early birds (who wake up early in the morning and are more active in the first hours of the day) and excludes night owls (who instead are more active during the evening and night). These results could be useful in preparing athletes for endurance competitions. From France to the Caribbean
To study sailors’ sleep management, the researchers focused on the participants in the Mini Transat La Boulangère, one of the most crowded solo regattas. On odd-numbered years, more than 80 sailors race across the Atlantic Ocean for 4,050 miles and live aboard 6 m boats. The race presents two stops. The boats set sail from France west coast, La Rochelle, then after 1,350 miles they stop at the Canary Islands. From there, they cross the Atlantic for 2,700 miles and, thanks to the trade winds, they reach Martinique, an island in the Caribbean. Researchers analyzed a sample of 42 skippers, gathering data and information about the training weeks preceding the regatta. They asked the skippers about the quality of their sleep, their level of somnolence and their chronotype. Sleep Management Strategies
The analysis reveals that more than half of the skippers in the sample (55%) choose to prep for the regatta by devising a sleep management strategy. “Expert skippers often make this choice,” says Plazzi. “Indeed, expert sailors with a track record of miles and miles of offshore sailing are more mindful of the importance of sleep management.”
Which strategies do they employ? The most frequent strategy (52%) is sleep extension, that is stoking up on sleep before the race so to have a sort of “sleep storage” available during the competition when sleep time and quality inevitably decrease. 26% of the skippers adopted polyphasic sleep. In polyphasic sleep, a nap schedule has to be followed throughout the day. This strategy allows to be more vigil and to be absent from the rudder for limited periods of time. Finally, 22% of the sample opted for gradual sleep deprivation to strike a balance between a short period of restorative sleep and the psycho-physical conditions to get the race done. Skippers Are Not “Night Owls”
Chronotype is another interesting matter here. It represents propensity for being more active at a particular time of the day, thus influencing sleep and wake periods. In this case, researchers observed a “natural selection” among the skippers of the Mini Transat La Boulangère. 40% of the sample presents the morning-type profile. These skippers can be defined as “early birds”: they wake up early, are more active in the morning and go to sleep early. 60% of the skippers in the sample belongs instead to an intermediate chronotype, the so-called “hummingbird”: they do not show a preponderant preference towards being active in the morning or at night. No one in the sample displayed the third chronotype (eveningness or “night owls”), according to which a person tends to go to bed late and wake up late in the morning. “In our sample, the morning-type chronotype is definitely overrepresented: ‘early birds’ represent 25% of the general population,” Plazzi says. “Even more surprising is the fact that there aren’t any ‘night owls’ in our sample. This means that ‘eveningness’ represents a disadvantage in endurance competitions.”
Chronotype and Strategies
Sleeping management strategies and chronotype also intertwine. A striking majority of the skippers adopting sleeping management strategies belongs to the intermediate-type profile, while those who do not follow sleeping schedules belong to the morning type. According to the researchers, this result can hint at a lack of flexibility among the “early birds.” Indeed, it would seem more difficult for them to radically change their sleep-wake cycles. “The results of our study clearly show the importance of choosing a sleeping management strategy during the psycho-physical preparation for extreme competitions such as single-handed transatlantic crossings,” Plazzi says. “Our next step will be to closely monitor sleep-wake cycles both during the training and during the race. In this way, we will be able to devise increasingly effective and precise sleep management strategies.”
Share:

Pre-Event Sleep Extension Is the Most Common Sleep Management Strategy Employed During Solo Sailing Race

Email giuseppe.plazzi@unibo.it
Purpose: To evaluate chronotype and the sleep management strategy adopted by sailors before the offshore solo sailing race “Mini Transat La Boulangère”. As secondary aim, we assessed whether adopting pre-race sleep management strategy influences performance at race. Materials and Methods: Forty-two solo sailors completed questionnaires on sleep quality, sleepiness, chronotype and an ad hoc questionnaire on the pre-race sleep management strategy adopted. Arrival times, separately for each race’s leg, were provided by the race organization team. Results: Solo sailors present mainly with a morning-type (40%) and intermediate-type (60%) chronotype, while none have an evening-type chronotype. Fifty-five percent of sailors adopted pre-race sleep management strategy. Sailors that adopted strategy have travelled more miles in offshore compared to sailors that did not adopt strategy (p< 0.05). Significant differences emerged in rMEQ scores, with sailors that adopted strategy presenting lower score compared to sailors that did not adopt sleep strategy (p< 0.05), as well as in chronotype distribution with morning-type sailors that are less likely to adopt pre-race sleep management strategy compared to intermediate type sailors (p< 0.05). No differences emerged in final arrival times and in arrival time at leg1 and leg2. The most commonly adopted strategy (52% of sailors) consists of sleep extension, followed by the polyphasic sleep (26%), and sleep deprivation (22%) strategy. Sailors trained in polyphasic sleep have higher ESS than sailors trained in sleep deprivation (p< 0.05). Conclusion: Morning-type chronotype is overrepresented in this large cohort of solo sailors compared to the general population; moreover, chronotype seems to influence the adoption of sleep management strategy. A little over half of solo sailors participating in the Mini Transat trained in sleep management strategy before the race; however, neither the general adoption of pre-race sleep management strategy nor the adoption of a specific sleep strategy seems to significantly influence final arrival times. Keywords: sleep, solo sailing, chronotype, sport medicine, training
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License . By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms .

Pre-Race Sleep Management Strategy and Chronotype of Offshore Solo Sailors

Share this article
BOCA RATON, Fla., April 21, 2020 /PRNewswire/ --
Drug-free, nonprescription REMfresh®, the first continuous release and absorption melatonin (CRA-melatonin®), ranks for the third year as the #1 recommended modified-release melatonin brand, for the second year as the #1 recommended melatonin brand and for the first year as the #1 recommended nonprescription sleep aid brand by primary care physicians with certification in sleep disorders1
In a pivotal trial, approved after peer review and then published, the REM Absorption Kinetics Trial (REMAKT), demonstrated REMfresh mimics the body's own 7-hour Mesa Wave® a natural pattern of melatonin blood levels during a normal night's sleep cycle
A second study, the 1,116 patient-reported outcomes (PRO) study, REMfresh  Duration Validation (REMVAL), peer-reviewed and then presented at a major sleep medicine conference, SLEEP 2019, provided confirmatory real-world evidence of the 7-hour action of REMfresh, a 99% ultrapure melatonin
Physician's Seal, LLC®, innovators of REMfresh® (CRA-melatonin®), a clinically studied, drug-free, nonprescription sleep brand, revealed positive results of a nationwide survey conducted among a representative sample of U.S. primary care physicians with certification in sleep disorders. These primary sleep specialists broadened their endorsement for REMfresh as the:
#1 recommended modified-release melatonin brand for the third consecutive year;
#1 recommended melatonin brand for the second consecutive year; and
#1 recommended nonprescription sleep aid brand for the first year.1
Melatonin: The Body's Natural Sleep Ingredient
Melatonin is produced by the pineal gland in the brain and is the body's natural sleep ingredient. Melatonin levels normally begin to rise in the mid-to-late evening and remain high for the majority of the night. Levels begin to decline towards early morning as the body's wake cycle is triggered. Recent research demonstrates that sleep is a strong regulator of immune function, essentially contributing to the regulation of adaptive immunity.2 The study also shows that chronic sleep loss poses an enhanced risk for various diseases as a consequence of persistent low-grade systemic inflammation and immunodeficiency, characterized by an enhanced susceptibility to infections, which have detrimental effects on health.2
"Now more than ever, the role of sleep has become paramount in immune health," said David C. Brodner, M.D., a leading sleep specialist who is Double Board-Certified in Otolaryngology – Head and Neck Surgery as well as Sleep Medicine, Founder and Principle Physician at the Center for Sinus, Allergy, and Sleep Wellness, in Palm Beach County, Florida and Senior Medical Advisor for Physician's Seal, LLC. "During this particularly challenging time in our nation, any way to improve the nation's sleep deficit will greatly improve public health." Dr. Brodner continued, "There is growing, widespread adoption of REMfresh among primary care physicians with certification in sleep disorders and an increased willingness to recommend this brand based on their real-world experience in receiving positive feedback from their patients who suffer from sleep disturbances. "   
Over 5,000 physicians are recommending REMfresh and the number of REMfresh endorsers among nurse practitioners, physicians assistants and pharmacists is growing rapidly. About IQVIA ProVoice Survey
ProVoice has the largest sample size of any professional healthcare survey in the U.S., with nearly 60,000 respondents across physicians, nurse practitioners, physician assistants, optometrists, dentists and hygienists, measuring recommendations across more than 120 over-the-counter categories. Manufacturers use ProVoice for claim substantiation, promotion measurement and HCP targeting. IQVIA fielded a U.S. survey among a representative sample of primary care physicians with certification in sleep disorders between February 26, 2020, through March 16, 2020, for Physician's Seal. The ProVoice survey methodology validated the claim at a 95 percent confidence level that "REMfresh® is the #1 recommended modified-release melatonin brand for the third year, #1 recommended melatonin brand for the second year and  #1 recommended nonprescription sleep aid brand for the first year by primary care physicians with certification in sleep disorders.1
IQVIA is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry formed through the merger of IMS Health and Quintiles. About Nonprescription REMfresh®
REMfresh® (CRA-melatonin®) is the first and only, continuous release and absorption formulation of 0.5mg (Lite), 2 mg and 5mg (Extra Strength) UltraMelÒ melatonin. UltraMel melatonin is a high-quality, 99 percent ultra-pure melatonin sourced, from an FDA DMF-approved facility in Western Europe, exclusively for Physician's Seal. REMfresh caplets, 99% ultrapure melatonin, continuously released and absorbed, over 7 hours, is designed to help a person fall asleep faster, stay asleep longer and experience quality sleep, such as deep sleep and REM sleep. REM Absorption Kinetics Trial (REMAKT), a U.S.-based randomized, crossover pharmacokinetic (PK) evaluation study in healthy, non-smoking adults compared REMfresh (CRA-melatonin) with a market-leading, immediate-release melatonin (IR-melatonin). The study results, which were approved after peer review and then published in Primary Care Companion for CNS Disorders in August 2019, showed that melatonin levels with REMfresh exceeded the targeted sleep maintenance threshold for a median of 6.7 hours, compared with 3.7 hours with the leading IR-melatonin. Conversely, the levels of the market-leading IR-melatonin formulation dramatically increased 23 times greater than the targeted levels of exogenous melatonin for sleep maintenance and had a rapid decline in serum levels that did not allow melatonin levels to be maintained above target beyond 4 hours. Additionally, the published paper noted the advance beyond a prolonged release prescription melatonin available in Europe. The author's concluded that "CRA-melatonin shows an enhancement over the release profile of prolonged release melatonin(PR-melatonin) by extending in vivo exposure to 7 hours, making it an important advancement in the use of melatonin as a chronobiotic, potentially with drug-free hypnotic effects to initiate and maintain sleep. "3
Another study, the post marketing REMfresh Duration Validation (REMVAL) study was peer reviewed and then presented at SLEEP 2019, the 33rd Annual Meeting of the Associated Professional Sleep Societies (APSS), LLC, a joint partnership of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS). This 1,116-patient REMVAL study was designed to obtain clinically relevant information about patients' past usage of melatonin and non-melatonin sleep aids, sleep patterns prior to taking CRA-melatonin, sleep duration before and after taking CRA-melatonin, frequency of CRA-melatonin usage, improvement in sleep latency, sleep maintenance and sleep quality after taking CRA-melatonin, and overall satisfaction with CRA-melatonin. In the study, patients with sleep disturbances in the general population received a sample of REMfresh from their physicians and were invited to complete a 13-question online survey. After taking REMfresh, the majority (78.8 percent) of patients achieved a sleep duration of ³ 6 hours (p<.0001). More than 91 percent of patients reported a major/moderate improvement in sleep onset, maintenance and sleep quality (p<.0001). Of the 30.7 percent of patients (342 in total), who reported never having taken other brands of melatonin, 99.4 percent indicated they were likely or very likely to continue taking REMfresh for their sleep issues.4
REMfresh was designed as a hydrogel matrix tablet with its patented, scientifically advanced Ion-Powered Pump® (IPPÒ) technology, pioneered by Physician's Seal. Initially, there is a rapid release of the melatonin from the surface of the tablet in the acidic environment of the stomach. As the tablet moves into the higher pH of the small intestine, where melatonin is unlikely to dissolve, food grade organic acid built inside the tablet, helps maintain a lower pH within the tablet over 7 hours, to allow for continuous release and absorption of active melatonin throughout the GI tract. REMfresh is a dietary supplement and is regulated under the Federal Dietary Supplement Health and Education Act, which does not require pre-approval. Melatonin has been in common use for over two decades and has a well-established profile of safe use by millions of people around the world. Physicians note that melatonin has an advantage when it comes to morning dysfunction, drowsiness or unusual night occurrences such as sleepwalking. Additionally, the REM Safety Update at 24 months (REMSU24), a 24-month post-marketing safety study of more than 320,000 users showed no pattern of side effects.5 As with all supplements, individual results may vary. REMfresh is non-habit forming and does not contain narcotics, hypnotics, barbiturates, sedatives, antihistamines, alcohol or other harsh additive chemicals. The usual adult recommended dose is 1-2 tablets 30-90 minutes before bedtime. Specific dosing instructions found on the back of the box should be followed for proper use of supplements. REMfresh is available in 0.5mg (Lite), 2mg and 5mg (Extra Strength) versions. About Physician's Seal®  
Physician's Seal® is the Innovator of REMfresh®, the first and only continuous release and absorption, 99 percent ultrapure melatonin (CRA-melatonin™), that mimics the way the body naturally releases and takes up melatonin over a 7-hour period. Physician's Seal (PS), founded in 2015, is a privately held company based in Boca Raton, Florida. It is committed to bringing cutting-edge life science applications to doctors and their patients. For more information, visit www.REMfresh.com . Physician's Seal's sister subsidiary, IM HealthScience® (IMH), is the innovator of the two medical foods IBgard® and FDgard® for the dietary management of Irritable Bowel Syndrome (IBS) and Functional Dyspepsia (FD or recurring meal-triggered indigestion), respectively. IMH rounds out its line of digestive products with Fiber Choice®, a well-known, natural prebiotic chewable daily fiber that helps support regularity. IMH® is a privately held company based in Boca Raton, Florida. It was founded in 2010 by a team of highly experienced pharmaceutical executives. Both PS and IMH are dedicated to developing products to address overall health and wellness in digestive health and sleep. The Physician's Seal and IM HealthScience advantage comes from developing products based on patented, targeted-delivery technologies, including IPP® (Ion-Powered Pump®) and SST® (Site Specific Targeting®) technologies. For more information, visit www.imhealthscience.com to learn about the company, or www.IBgard.com , www.FDgard.com and www.FiberChoice.com . Copyright © 2020 Remfresh® This information is for educational purposes only and is not meant to be a substitute for the advice of a physician or other health care professional. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. You should not use this information for diagnosing a health problem or disease. REMfresh is intended to relieve occasional sleeplessness. Statements made in this release rely upon reviews of literature, input from PS's advisors and PS's own expertise. There may always be other opinions or emphasis points. Some of the statements from different sources may not mesh with each other. There may be inadvertent inaccuracies that PS is not aware of. Space limitations in this release only allow limited reference to some guidelines or practices which may, or may not, be fully agreed to by all scientific, medical or regulatory experts. For any of PS's products this release does not make or have any intent to make drug claims or any comparison or implied claims against FDA approved interventions for sleep disorders. Any comments on any products are based on literature reviews and input from PS's own advisors. There may be others who have other points of view. Pre-clinical findings do not always correlate with clinical or real-world findings. The reader is urged to check all current information, including the latest website disclosures and/or package inserts, of any of the medical products mentioned here, as information, including government regulations, changes all the time. The statements of individual opinions are those of the individuals quoted and do not necessarily reflect opinions of PS. Please fully read all disclaimers/clarifications/explanations. PS disclaims any injury or alleged injury resulting from any ideas, methods, instructions or products referred to here. Health care practitioners should use their independent, professional judgment in helping their patients best manage their sleep conditions. The company will strive to keep information current and consistent but may not be able to do so at any specific time. Generally, the most current information can be found on www.REMfresh.com . Individual results may vary. REMfresh is protected by U.S. Patents No. : 8,691,275; 9,186,351; 9,241,926;  9,549,900; 10,226,447. Keep out of reach of children. Store at room temperature. Individual results may vary. Do not use if blister is torn or ripped or if there is any other evidence of tampering. Consult a physician if using any supplement for the first time. Please read package insert and the website for more information. References:
IQVIA. ProVoice Survey REMfresh is the #1 recommended modified-release melatonin brand for the third consecutive year, #1 recommended melatonin brand for the second consecutive year and #1 recommended nonprescription sleep aid brand for the first year for sleep management; 2020 [Among primary care physicians with certification in sleep disorders]. Besedovsky, L., Lange, T. & Born, J. Sleep and immune function. Pflugers Arch - Eur J Physiol 463, 121–137 (2012). https://doi.org/10.1007/s00424-011-1044-0 . Seiden DJ, Shah SM. A Randomized, Crossover, Pharmacokinetics Evaluation of a Novel Continuous Release and Absorption Melatonin Formulation versus a Same Strength Immediate-Release Formulation. Primary Care Companion for CNS Disorders. 2019. 21(4):19m 02450. Brodner DC, Seiden DJ, Shah SM (2019). Observed Hypnotic Effects with a Continuous-Release Ion Powered Pump Melatonin Delivery System: Self-Reported Patient Outcomes Study Results Demonstrating Improvement in Sleep Duration and Quality. (Abstract 0399). Poster Presented at SLEEP 2019, San Antonio, Texas. Physician's Seal (2019). Real-world data from surveillance study confirms excellent safety and tolerability profile of REMfresh at 24 months (REMSU-24); Data on file; Press Release 9/27/19. SOURCE Physician's Seal

The Immune Health Benefit Of Sleep Becomes More Important Than Ever Before, As Primary Care Sleep Specialists Broaden Their Endorsement Of Remfresh®, A Pharmaceutical Science Advance In Sleep Management, As Their #1 Recommended Nonprescription Sleep Brand

Acquired

VieMed, wholly owned by Sleep Management LLC, is a disease management company. The company offers an effective home treatment model that integrates easily into the processes of referral partners. While our Respiratory Care Practitioners deliver therapy and counseling to patients in their home utilizing the most effective technology available, our Care Consultants work with hospitals, ACO's, SNF's and other referral sources to simplify the administrative process of transitioning patients from hospital to home care.

Date	6/10/2015
Round	Acquired
Amount
Investors	Patient Home Monitoring
Valuation
Revenue	$0.00B ((9.99x)) FY 1234
Sources	1

First funding	6/10/2015
Last Funding	6/10/2015
Investor	Patient Home Monitoring
Rounds	1 Acquired
Board Seats
Type	Corporation
Location	Kentucky

Wells Fargo Success Story

Professional Services

Platform Overview

Sleep Management

Investors Count

Funding, Valuation & Revenue

Sleep Management Investors